Characterization of immunotoxins active against ovarian cancer cell lines.

The purpose of the present study was to develop immunotoxins directed against human ovarian carcinoma cells. Four monoclonal antibodies (260F9, 454C11, 280D11, and 245E7) were chosen because they were found to bind to various ovarian carcinoma cell lines. These antibodies were covalently linked to either Pseudomonas exotoxin (PE) or ricin A chain (RTA), and the conjugates were tested against five ovarian cancer cell lines (OVCAR-2, -3, -4, -5; A1847). The ability of the immunotoxins to inhibit both protein synthesis and colony formation was evaluated. Qualitatively similar results were obtained for both types of assays. Usually, PE conjugates were more toxic than their corresponding RTA conjugates. 454C11-PE was very toxic for all ovarian carcinoma lines, whereas 454C11-RTA had low activity. Both 260F9-PE and 260F9-RTA were active in all OVCAR cell lines but not in A1847 cells. 280D11-PE was toxic for OVCAR-4; otherwise, 280D11-PE and RTA conjugates of both 280D11 and 245E7 had little activity. Specificity of immunotoxin action was shown by competition by excess antibody, nontoxicity in nontarget cells, and inactivity of an irrelevant immunotoxin. To investigate the basis of antibody-dependent differences in activity of the various immunotoxins, antibody uptake was studied in OVCAR-2 cells, and the results indicate that antibody internalization is one important factor in the activity of immunotoxins.

[1]  A. Frankel,et al.  Tissue distribution of breast cancer-associated antigens defined by monoclonal antibodies. , 1985, Journal of biological response modifiers.

[2]  I. Pastan,et al.  Potentiation of cytotoxic activity of immunotoxins on cultured human cells. , 1985, Cancer research.

[3]  A. Frankel,et al.  Evaluation of monoclonal antibodies for the development of breast cancer immunotoxins. , 1985, Cancer research.

[4]  I. Pastan,et al.  Anti-transferrin receptor antibody linked to Pseudomonas exotoxin as a model immunotoxin in human ovarian carcinoma cell lines. , 1985, Cancer research.

[5]  R. Ozols,et al.  Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice. , 1984, Cancer research.

[6]  R C Young,et al.  Experimental model systems of ovarian cancer: applications to the design and evaluation of new treatment approaches. , 1984, Seminars in oncology.

[7]  T. Waldmann,et al.  Pseudomonas exotoxin-anti-TAC. Cell-specific immunotoxin active against cells expressing the human T cell growth factor receptor. , 1984, The Journal of clinical investigation.

[8]  P. Casellas,et al.  Kinetics of cytotoxicity induced by immunotoxins. Enhancement by lysosomotropic amines and carboxylic ionophores. , 1984, The Journal of biological chemistry.

[9]  J. Uhr,et al.  Cytotoxicity of a cell-reactive immunotoxin containing ricin A chain is potentiated by an anti-immunotoxin containing ricin B chain , 1984, The Journal of experimental medicine.

[10]  B. Foxwell,et al.  Blockade of the galactose-binding sites of ricin by its linkage to antibody. Specific cytotoxic effects of the conjugates. , 1984, European journal of biochemistry.

[11]  S. Ramakrishnan,et al.  Inhibition of human acute lymphoblastic leukemia cells by immunotoxins: potentiation by chloroquine. , 1984, Science.

[12]  J. Whang‐Peng,et al.  Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. , 1983, Cancer research.

[13]  C. Hopkins,et al.  Internalization and processing of transferrin and the transferrin receptor in human carcinoma A431 cells , 1983, The Journal of cell biology.

[14]  I. Pastan,et al.  Enhancement of toxicity of antitransferrin receptor antibody-Pseudomonas exotoxin conjugates by adenovirus. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[15]  D. Mason,et al.  Transferrin receptors in human tissues: their distribution and possible clinical relevance. , 1983, Journal of clinical pathology.

[16]  J. Uhr,et al.  Immunotoxins: a new approach to cancer therapy. , 1983, Science.

[17]  M. Sela,et al.  Chemotherapy by intravenous administration of conjugates of daunomycin with monoclonal and conventional anti-rat alpha-fetoprotein antibodies. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[18]  D. Neville,et al.  Kinetics of protein synthesis inactivation by ricin-anti-Thy 1.1 monoclonal antibody hybrids. Role of the ricin B subunit demonstrated by reconstitution. , 1982, The Journal of biological chemistry.

[19]  A. Pihl,et al.  Toxic lectins and related proteins , 1982 .

[20]  D. Gilliland,et al.  Antibody-directed cytotoxic agents: use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cells. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[21]  A. Pihl,et al.  Entry of lethal doses of abrin, ricin and modeccin into the cytosol of HeLa cells. , 1980, Experimental cell research.

[22]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.

[23]  D. Kabat,et al.  NAD-dependent inhibition of protein synthesis by Pseudomonas aeruginosa toxin,. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[24]  R. Knapp,et al.  The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma. , 1972, Cancer research.